Acute intestinal GVHD remains a major source of morbidity after allogeneic hematopoietic cell transplantation (HCT). a4b7 integrin is a cell surface molecule that mediates lymphocyte trafficking to intestinal tissue. In this analysis, peripheral blood was collected at the time of presentation of symptoms of acute GVHD and before any treatment. In all, 45 samples were collected and divided into three groups on the basis of subsequent evaluation: intestinal GVHD (n ¼ 15), skin GVHD (n ¼ 20) and no GVHD (n ¼ 10). Two patients developed intestinal GVHD after DLI. The no-GVHD group comprised 10 patients who presented with suspicious symptoms, but evaluation yielded other etiologies. Analysis by flow cytometry showed that intestinal GVHD patients had a significantly higher percentage of a4b7 integrin-expressing memory CD8 þ T cells (median 7.69%; lower and upper quartiles, 1.06% and 11.64%, respectively) compared with patients with skin GVHD (1.26%; 0.57% and 2.49%) and no GVHD (0.96%; 0.44% and 1.85%), P ¼ 0.03. No differences were found in a4b7 expression in any CD4 þ T-cell subsets or naive CD8 þ T cells. This study adds to the evidence that a4b7 integrin is involved in lymphocyte trafficking in acute intestinal GVHD.
INTRODUCTION
Acute GVHD remains a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). 1 Systemic corticosteroids remain the first-line therapy for acute GVHD; however, steroids will result in long-term remission of symptoms in only B50% of patients. 2, 3 Hence, novel treatment approaches for acute GVHD are sorely needed. a4b7 integrin is a cell surface molecule that mediates specific lymphocyte trafficking to the intestine and associated lymphoid tissue. [4] [5] [6] a4b7 integrin appears to have essential roles in the steps of 'tethering and slow rolling', as well as in 'temporary arrest' for both naive and effector T cells destined for intestinal tissue, 7 and thus represents an attractive target for the treatment of immunologic diseases of the intestine.
Two studies have previously suggested a role for a4b7 integrin in the trafficking of lymphocytes involved in acute intestinal GVHD in patients after allogeneic HCT. Our previous study analyzed the expression of a4b7 integrin on peripheral blood T-cell subsets from samples that had been collected within the month before the presentation of symptoms. Results suggested that the increased expression of a4b7 integrin on both memory CD4 þ and CD8 þ T cells correlated with the development of intestinal acute GVHD, however, the timing of sample collection was quite heterogeneous relative to the presentation of GVHD, and the samples were frozen previously. 8 Investigators at Vanderbilt University conducted another study investigating the significance of the expression of a4b7 integrin on suppressive regulatory (CD45RO þ CD25 þ Foxp3 þ CD127 lo ) T cells. They collected samples at the time of neutrophil engraftment after HCT and showed that decreased expression of a4b7 integrin on regulatory T cells correlated with the subsequent development of intestinal acute GVHD. 9 In this study, we analyzed peripheral blood samples collected on the day of presentation of symptoms suspicious for acute GVHD and before receiving any systemic treatment. Flow cytometry was performed on fresh blood samples, all collected from patients at the time of presentation of active symptoms. The expression of a4b7 integrin was found to be significantly increased on memory CD8 þ T cells in patients with active symptoms of acute intestinal GVHD, compared with patients with acute skin GVHD and those with no GVHD, suggesting that a4b7 integrin-expressing memory CD8 þ T cells may be a target for novel therapeutic approaches.
MATERIALS AND METHODS

Patients and samples
This study was approved by the Institutional Review Board of the DanaFarber/Harvard Cancer Center (DFHCC). After informed consent was obtained, peripheral blood samples were collected from patients who presented with symptoms suspicious for either intestinal or cutaneous acute GVHD at Massachusetts General Hospital. After clinical evaluation, the patients were then divided into three groups: intestinal GVHD, skin GVHD and no GVHD. The diagnosis of acute GVHD was made by the treating physicians, using clinical and pathological criteria and judgment. The treating physicians did not have access to any of the a4b7 integrin expression data presented here. Patients who had manifestations of both intestinal and skin GVHD were included in the intestinal group. Patients in the skin GVHD group had isolated skin GVHD only. Patients who had hepatic GVHD were excluded from the skin GVHD group, but not from the intestinal GVHD group. Patients with isolated hepatic GVHD were excluded 1 because of their rarity and the potentially similar trafficking patterns between lymphocytes homing to the liver and intestines. Patients in the skin GVHD and no GVHD groups were also combined into one group for additional analysis. The grading of acute GVHD was based upon previously published criteria. 10 Although samples were collected at the time of symptoms, assignment into groups was done after the evaluation was complete. Patients who presented with symptoms after day-100 of HCT were included, consistent with the recent consensus definitions of acute GVHD. All samples of blood were collected in EDTA tubes, and mononuclear cells were isolated by density gradient centrifugation.
Flow cytometry
Flow cytometry was performed within 24 h of sample collection on fresh cells and before the determination of the diagnosis for each patient. Clinical data for each patient were not available to those performing and interpreting the results of flow cytometry. Cells were stained using an Ab panel consisting of conjugated Abs against CD45, CD3, CD4, CD8, CD45RO and a4b7 integrin. These reagents were purchased from BD Biosciences (San Jose, CA, USA), with the exception of anti-a4b7 integrin (ACT-1), which was provided by Millennium Pharmaceuticals, Inc. (Cambridge, MA, USA) and conjugated at Dana-Farber Cancer Institute (DFCI) with Cy5 using PBS sodium bicarbonate dialysis and column fractionation. The cells were then analyzed using a FACSCanto II (BD Biosciences). T-cell subsets were defined as follows:
Results were analyzed using FACSDiva (BD Biosciences). a4b7 integrin positivity in the Cy5 channel was determined using a fluorescence-minus-one gating strategy, utilizing all but the anti-a4b7 integrinCy5 Ab to assess background and nonspecific staining within the Cy5 channel. Results were quantified as both the percentage of each T-cell subset and the absolute number of cells (cells/mL) in each T-cell subset expressing a4b7 integrin.
Statistical analysis
For comparison of baseline characteristics, the Wilcoxon, Kruskal-Wallis and chi-square tests were used when appropriate. For comparison of a4b7 expression on each T-cell subset, the Wilcoxon test was used when comparing two groups (intestinal GVHD vs non-intestinal GVHD) and the Kruskall-Wallis test was used when comparing three groups (intestinal GVHD vs skin GVHD vs no GVHD). Logistic regression was used to assess whether donor a4b7 integrin expression was associated with intestinal GVHD when adjusting for donor type (matched related donor vs matched unrelated donor) and conditioning regimen (myeloablative vs reduced intensity). Spearman's coefficient testing was used to analyze whether the levels of a4b7 integrin expression correlated with the clinical severity of intestinal GVHD.
RESULTS
Patient characteristics
Baseline characteristics of the 45 patients are shown in Table 1 .
A total of 15 patients received a myeloablative conditioning regimen, whereas 30 patients underwent reduced-intensity HCT. In all, 25 patients received stem cells from matched related donors, whereas 20 patients received transplants from matched unrelated donors, with all patients receiving PBSC grafts. All patients received calcineurin inhibitor-based GVHD prophylaxis with additional MTX, sirolimus or a combination. Of the 20 patients receiving unrelated transplants, 16 received antithymocyte globulin during conditioning. As shown in Table 1 , baseline characteristics did not differ significantly between the three groups. Two patients in the intestinal GVHD group had samples collected after developing GVHD in the context of DLI. The onset of GVHD varied between day 22 and day 186 after HCT or DLI, with the median time to development of GVHD being 48 days (range 23, 100) in the intestinal GVHD group and 66 days (range 22, 186) in the skin GVHD group. Two patients in the intestinal GVHD group had hepatic disease as well, one grade 3 and one grade 4. Median time to sample collection in the no GVHD group was 60 days after HCT (range 21, 194) . Of the patients in the no GVHD group (n ¼ 10), seven presented with diarrhea symptoms and a4b7 integrin expression in acute GVHD Y-B Chen et al three presented with a skin rash. Of the seven patients who presented with diarrhea, there were two cases of viral gastroenteritis and antibiotic-associated diarrhea and one case each of gastrointestinal bleeding from gastritis, Clostridium difficile colitis and narcotic withdrawal. All samples in the skin and intestinal GVHD groups were collected before the administration of steroids or other immunosuppressives for the treatment of GVHD.
Expression of a4b7 Integrin Results of flow cytometry quantification of the expression of a4b7 integrin on peripheral blood T-cell subsets are shown in Table 2 . Analysis showed that there was a significant increase in the percentage of memory CD8 þ T cells expressing a4b7 integrin in the intestinal GVHD group (median 7.69%; lower and upper quartiles of 1.06%, 11.64%) compared with the skin GVHD (median 1.26%; 0.57%, 2.49%) and no GVHD (median 0.96%; 0.44%, 1.85%) groups, respectively (P ¼ 0.03), and when compared with the combined skin GVHD and no GVHD group (median 1.00%; 0.57%, 2.22%) (Figure 1a , P ¼ 0.01). In addition, when the results were quantified as the absolute number of cells/mL in each T-cell subset, the expression of a4b7 integrin was similarly increased in the memory CD8 þ T-cell subset (4.0; 2.0, 7.0) compared with the skin GVHD (2.0; 1.0, 3.3) and no GVHD (1.0; 1.0, 1.0) groups, respectively (P ¼ 0.02), and when compared with the combined skin GVHD and no GVHD groups (1.0; 1.0, 3.0) (Figure 1b , P ¼ 0.03). Expression of a4b7 integrin was also significantly higher on the memory CD4 þ subset for patients with intestinal GVHD when analyzing by cells/mL, but this was not the case when expressed as a percentage of lymphocytes. The expression of a4b7 integrin was also quantified by mean fluorescence intensity in the memory CD4 þ and CD8 þ subsets, and there was no significant difference between the groups when measured by this method (data not shown).
Representative histograms from each group are shown in Figure 2 . a4b7 integrin expression was not significantly different on naive CD4 þ T cells or CD8 þ T cells. Expression of a4b7 integrin was not significantly affected by time after HCT, conditioning intensity, donor type, GVHD prophylaxis regimen, the use of antithymocyte globulin and underlying diagnosis (data not shown). Logistic regression analysis showed that after adjustment for donor type (related vs unrelated, P ¼ 0.97) and conditioning regimen (myeloablative vs reduced intensity, P ¼ 0.22) the diagnosis of acute intestinal GVHD was still significantly associated with the increased expression of a4b7 integrin, with an odds ratio of 1.54 (95% CI 1.12, 2.12), P ¼ 0.008. Further analysis showed that the level of expression of a4b7 integrin on memory CD8 þ T cells in the intestinal GVHD group did not have a significant correlation with the clinical grade of the disease (data not shown, P ¼ 0.29). For four patients with intestinal GVHD, subsequent samples were collected after successful treatment. These later samples were obtained after 91-104 days of initial sample collection. The percentage of memory CD8 þ T cells expressing a4b7 integrin was lower in each patient after successful treatment of intestinal GVHD, and this is shown in Figure 3 .
DISCUSSION
Recently, several murine models have illustrated that lymphocyte migration after HCT involves sequential trafficking of naive donor T cells to host secondary lymphoid tissue followed by specific infiltration into target organs, which leads to the clinical manifestations of acute GVHD. 11, 12 Defining the specific adhesion molecules involved in this process of lymphocyte trafficking may provide novel opportunities for the monitoring, prophylaxis and treatment of acute GVHD after HCT.
In our previous retrospective study conducted on frozen samples collected within the month before the onset of the symptoms of GVHD, we analyzed the surface expression of a4b7 integrin on similar peripheral blood T-cell subsets from three groups of patients after HCT: (1) no GVHD, (2) skin GVHD and (3) gut GVHD (with or without skin or liver involvement). Our results showed that a4b7 integrin expression was significantly increased on both memory and naive CD4 þ and CD8 þ T cells, but most strikingly in the memory subsets, in patients who subsequently developed intestinal GVHD. Indeed, the expression of a4b7 integrin on CD4 þ and CD8 þ memory T-cell subsets in patients with intestinal GVHD was at least 10-fold higher compared with patients with skin GVHD or no GVHD. In addition, rectal biopsies consistent with intestinal GVHD had evidence of a4b7 þ mononuclear cells located within small terminal mucosal blood vessels. Given that samples had been originally collected on other protocols, there was significant heterogeneity in terms of the timing of sample collection in relation to the onset of symptoms of acute GVHD, and all analyses were performed on previously frozen samples.
In this study, samples were collected on the day of presentation of symptoms of acute GVHD and before the initiation of treatment with systemic corticosteroids or additional immunosuppression. Furthermore, flow cytometry was performed within 24 h of collection on fresh cells rather than on frozen specimens. Although there was the expected variation in clinical characteristics such as underlying diagnosis, donor source (matched related donor vs matched unrelated donor), conditioning regimen (myeloablative vs reduced intensity) and GVHD prophylaxis regimen, there were no significant differences in these characteristics between the groups. A significant increase in a4b7 integrin expression was observed on memory CD8 þ T cells from patients who were diagnosed with intestinal acute GVHD, even after adjusting for donor type and conditioning intensity, compared with patients with skin GVHD or no GVHD. It is worth noting that when the data are presented in terms of cells/mL (absolute numbers) the memory CD4 þ population does show a significant difference, however, we believe that the relative number is more telling given the variations in lymphocyte counts after HCT. To fully reconcile the kinetics of a4b7 integrin expression on different CD4 and CD8 T-cell subsets, a large study with serial sample collection will be required, and such a study has completed accrual at our institutions. Preliminary results were presented on the first 84 patients and suggested that increased expression of a4b7 integrin on memory CD4
þ T cells at day þ 15 after HCT correlated with increased rates of nonrelapse mortality and decreased OS. GVHD end points could not be analyzed given the too few cases of significant intestinal GVHD in this early cohort. 13 It is possible that early injury or inflammation from conditioning or other etiologies triggers a CD4 þ response first (which is reflected in a4b7-expressing memory CD4 þ T cells), which then becomes predominantly CD8 þ if intestinal GVHD is triggered. This might explain why our previous study shows that a4b7 integrin is increased on both CD4 and CD8 T cells given the heterogeneity of the timing of sample collection in that study; however, this study, where all samples are collected at the time of symptoms, shows only increased expression on CD8 þ memory T cells.
Although this study includes a relatively limited number of patients, all samples were collected at the time of presentation of symptoms and before the initiation of steroid therapy, and thus are uniform in their timing relative to the onset of acute GVHD. Memory T cells were defined in this study by the expression of CD45RO, which admittedly has limitations. In our next generation of studies, we have added CD62L to be able to differentiate between effector memory and central memory T cells and are considering adding CCR7 or CD27. In addition, our recent data would suggest that CD30 may be an important marker of activation in acute GVHD, 14 and investigation of coexpression of CD30 and a4b7 integrin is underway. Samples from four patients after successful treatment of intestinal GVHD showed decreases in a4b7 expression on memory T cells, suggesting that this could potentially be a biomarker correlating with disease response; however, a much larger sample size is clearly needed for confirmation.
The data presented here are not intended to validate the expression of a4b7 integrin as a predictive or diagnostic biomarker for acute intestinal GVHD, as serial samples with a time-matched control population would be needed for that purpose, and such a study has completed accrual at our institutions with ongoing sample collection. Rather, the results of this study add to the evidence that a4b7 integrin expression on memory CD8 þ T cells is associated with clinically significant acute intestinal GVHD, and thus represent a potential novel target for therapy.
Although no other human studies have investigated the specific mediators of intestinal lymphocyte trafficking in GVHD of the intestine, several experiments have been performed in murine models with inconsistent conclusions. Murai et al. 15 reported that Peyer's patch-deficient host mice did not develop acute GVHD after HCT, and blocking access to Peyer's patch via a MoAb against MAdCAM-1, the ligand for a4b7 integrin, protected mice from acute GVHD. Other investigators showed in separate studies that purging donor cells of a4b7 þ T cells or using a selective b7 integrin knockout as the source of donor stem cells resulted in a significant reduction in intestinal GVHD in terms of overall incidence, clinical and histological manifestations and associated mortality. 16, 17 In contrast, other studies suggested that knockout of b7 was insufficient to modify intestinal GVHD, 18 and that blocking entry to specific secondary lymphoid organs (either peripheral lymph nodes or Peyer's patches) had no effect on GVHD, suggesting redundancy in secondary lymphoid tissue compartments. 19, 20 Drawing general conclusions from these individual studies is difficult because of differences in the immunology of GVHD specific to the individual mouse models of HCT used in each of these separate studies. The evidence does support the theory that acute GVHD is initiated by allogeneic activation in secondary lymphoid tissue, with the induction of a specific trafficking phenotype dependent on the location of the secondary lymphoid tissue. These effector cells, which possess this organ-specific trafficking phenotype, are a biologically plausible target for therapeutic purposes without potentially causing global immunosuppression.
Recently, investigators from the University of Pennsylvania presented preliminary results of a phase I/II human clinical trial using an oral antagonist of the chemokine receptor CCR5 for GVHD prophylaxis and showed a decreased incidence of acute GVHD at day 180 after HCT when compared with a historical control group, suggesting for the first time that GVHD could potentially be modified by inhibitors of leukocyte trafficking. 21 Targeting a4 integrin has already been shown to be efficacious in the form of natalizumab for patients with multiple sclerosis 22 and inflammatory bowel disease; 23 however, there have been several patients who have developed JC (John Cunningham) virusassociated progressive multifocal leukoencephalopathy after such a treatment. 24 Targeting a4b7 integrin will likely not put patients at risk for this serious complication, as immunologic protection of the central nervous system should remain intact given the specificity of a4b7 integrin for intestinal tissue. A specific MoAb (vedolizumab) has already been developed against a4b7 integrin and is being used in ongoing clinical trials for the treatment of inflammatory bowel disease, 25 and we plan to test this approach for the treatment of intestinal GVHD.
In summary, our data demonstrate the increased expression of a4b7 integrin on the surface of memory CD8 þ T cells in patients at the time of presentation of acute intestinal GVHD compared with patients with acute skin GVHD and patients without any acute GVHD after allogeneic HCT. In addition, we await the results of a large study prospectively collecting serial blood samples from 200 patients after allogeneic HCT, which may validate that the expression of a4b7 integrin on memory T cells can be a predictive or diagnostic biomarker for intestinal acute GVHD, as our previous study had suggested. 8 The population of memory CD8 þ T cells that have an increased expression of a4b7 integrin in this study is an intuitive target for novel treatment approaches of acute intestinal GVHD.
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